Related Experiment Video
Updated: Aug 5, 2025

Construction and Implantation of a Microinfusion System for Sustained Delivery of Neuroactive Agents.
Published on: March 17, 2008
A Micro-In-Macro Gastroretentive System for the Delivery of Narrow-Absorption Window Drugs
Mershen Govender1, Thankhoe A Rants'o1, Yahya E Choonara1
1Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa.
Abstract:
A micro-in-macro gastroretentive and gastrofloatable drug delivery system (MGDDS), loaded with the model-drug ciprofloxacin, was developed in this study to address the limitations commonly experienced in narrow-absorption window (NAW) drug delivery. The MGDDS, which consists of microparticles loaded in a gastrofloatable macroparticle (gastrosphere) was designed to modify the release of ciprofloxacin, allowing for an increased drug absorption via the gastrointestinal tract. The prepared inner microparticles (1-4 µm) were formed by crosslinking chitosan (CHT) and Eudragit® RL 30D (EUD), with the outer gastrospheres prepared from alginate (ALG), pectin (PEC), poly(acrylic acid) (PAA) and poly(lactic-co-glycolic) acid (PLGA). An experimental design was utilized to optimize the prepared microparticles prior to Fourier Transition Infrared (FTIR) spectroscopy, Scanning Electron Microscopy (SEM) and in vitro drug release studies. Additionally, the in vivo analysis of the MGDDS, employing a Large White Pig model and molecular modeling of the ciprofloxacin-polymer interactions, were performed. The FTIR results determined that the crosslinking of the respective polymers in the microparticle and gastrosphere was achieved, with the SEM analysis detailing the size of the microparticles formed and the porous nature of the MGDDS, which is essential for drug release. The in vivo drug release analysis results further displayed a more controlled ciprofloxacin release profile over 24 h and a greater bioavailability for the MGDDS when compared to the marketed immediate-release ciprofloxacin product. Overall, the developed system successfully delivered ciprofloxacin in a control-release manner and enhanced its absorption, thereby displaying the potential of the system to be used in the delivery of other NAW drugs.
Insights
A novel micro-in-macro drug delivery system (MGDDS) enhances ciprofloxacin absorption for narrow-absorption window drugs. This gastroretentive and gastrofloatable system provides controlled release and improved bioavailability.
Area of Science:
- Pharmaceutical Sciences
- Biomaterials Science
- Drug Delivery Systems
Background:
- Narrow-absorption window (NAW) drugs face challenges with limited gastrointestinal absorption.
- Traditional drug delivery systems often fail to optimize absorption for NAW drugs.
- Ciprofloxacin, an antibiotic, serves as a model drug for NAW delivery challenges.
Purpose of the Study:
- To develop a micro-in-macro gastroretentive and gastrofloatable drug delivery system (MGDDS).
- To enhance the absorption of ciprofloxacin, a model NAW drug.
- To investigate controlled release and improved bioavailability of the MGDDS.
Main Methods:
- Fabrication of MGDDS using chitosan (CHT), Eudragit® RL 30D (EUD), alginate (ALG), pectin (PEC), poly(acrylic acid) (PAA), and poly(lactic-co-glycolic) acid (PLGA).
- Characterization using Fourier Transition Infrared (FTIR) spectroscopy and Scanning Electron Microscopy (SEM).
- In vitro and in vivo drug release studies in a Large White Pig model, including molecular modeling.
Main Results:
- FTIR confirmed successful polymer crosslinking; SEM visualized microparticle size and MGDDS porosity.
- In vivo studies demonstrated a controlled 24-hour release profile for ciprofloxacin.
- The MGDDS significantly enhanced ciprofloxacin bioavailability compared to immediate-release products.
Conclusions:
- The developed MGDDS effectively delivers ciprofloxacin in a controlled-release manner.
- The system shows significant potential for improving the absorption of other NAW drugs.
- MGDDS represents a promising strategy for overcoming limitations in NAW drug delivery.
Related Concept Videos
Drug Delivery: Enteral Route
Routes of Drug Administration: Enteral
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Factors Influencing Drug Absorption: Anatomical Parameters
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Additional Routes of Drug Administration
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...

